Quick Answer
Orchestra BioMed Holdings, Inc. reported Research And Development Expense of $58.19 million for the year ending 2025.
- Orchestra BioMed Holdings, Inc. showed an increase of +35.9% in Research And Development Expense from 2024 to 2025.
- This data is from Orchestra BioMed Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $3.47 million | Q2 2022: $5.03 million | Q3 2022: $5.90 million | Q1 2023: $8.25 million | Q2 2023: $8.50 million | Q3 2023: $8.56 million | Q1 2024: $9.11 million | Q2 2024: $11.13 million | Q3 2024: $11.60 million | Q1 2025: $13.48 million | Q2 2025: $13.85 million | Q3 2025: $14.03 million.
- Over the full 4 years of available data (2022 to 2025), Orchestra BioMed Holdings, Inc.'s Research And Development Expense has grown by 165.1%.
- Historical annual values: Fiscal year 2025: $58.19 million | Fiscal year 2024: $42.80 million | Fiscal year 2023: $33.82 million | Fiscal year 2022: $21.95 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: